Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Imaging of axSpA Remains an Adjunctive Tool

Key clinical point: MRI is a valuable but not definitive tool for evaluating axial spondyloarthritis (axSpA), agree both the experts and the data.

Major finding: Reflecting the limits of imaging, 28.1% of 131 patients were diagnosed with axSpA by rheumatologists but not radiologists.

Data source: Prospective analysis of consecutive patients.

Disclosures: Dr. Baraliakos reports extensive financial relationships with pharmaceutical companies. Dr. van Gaalen reports none.

Citation:

Baraliakos X et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):255-6. Abstract OPO344, doi: 10.1136/annrheumdis-2019-eular.5027